{"id":68604,"date":"2023-06-05T10:45:22","date_gmt":"2023-06-05T10:45:22","guid":{"rendered":"https:\/\/dailytalks.org\/?p=68604"},"modified":"2023-06-05T10:45:22","modified_gmt":"2023-06-05T10:45:22","slug":"novel-folr%ce%b1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=68604","title":{"rendered":"Novel FolR\u03b1-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer"},"content":{"rendered":"<p>Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by Ana Oaknin, Principal Investigator of the Vall d&#8217;Hebron Institute of Oncology&#8217;s (VHIO) Gynecological Malignancies Group, on the ground at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO&#8230;<br \/><a href=\"https:\/\/medicalxpress.com\/news\/2023-06-folr-targeting-antibody-drug-conjugate-recurrent.html\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Updated dose expansion data of the phase I STRO-002-GM1 study have been presented today by<\/p>\n","protected":false},"author":1,"featured_media":68605,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"class_list":["post-68604","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/06\/68604-novel-folrceb1-targeting-antibody-drug-conjugate-shows-promise-in-recurrent-epithelial-ovarian-cancer.jpg",90,90,false]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=41\" rel=\"category\">Americas<\/a>","tag_info":"Americas","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/68604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68604"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/68604\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/68605"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}